Targovax presents further positive clinical data from TG01 phase I/II trial at 2017 ASCO annual meeting
Oslo, Norway, 6 June 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target treatment-resistant solid tumors, today announces that it presented clinical data from the phase I/II clinical trial evaluating TG01 in resected pancreatic cancer in a poster presentation at the American Society of Clinical Oncology Annual Meeting 2017 (ASCO) on Saturday, June 3rd 2017. The study evaluated safety, immunological response and overall survival of TG01/GM-CSF and gemcitabine as an adjuvant therapy for treating